JIIM/
Articles/
2606004277
  • Open Access
  • Article

Dual Targeting of HER-2 and VEGFR-2 Receptors in Breast Cancer-Associated Migration and Metastasis

  • Masoom Raza *,   
  • Naveen Kumar,   
  • Seema Sehrawat

Received: 02 Feb 2026 | Revised: 18 May 2026 | Accepted: 15 Jun 2026 | Published: 30 Jun 2026

Abstract

There are various types and subtypes of breast cancer cells. One of the most aggressive forms is TNBC, which is characterised by the absence of common hormonal receptors such as HER-2, PR, and ER on the cancer cells. These cancers are difficult to treat, and there is an unmet need for innovative strategies to develop drug combinations that effectively target and cure them. Therefore, we adopted a precision medicine approach to treat TNBC. In this study, we used a combination of two different drugs, Lapatinib and Telatinib, which specifically inhibit tyrosine kinases. We determined the IC50 values for these drugs despite the lack of HER2 receptor expression in MDA-MB-231 cells. Cells treated with these drugs, both individually and together, showed reduced invadopodia formation and decreased cell proliferation. We also observed a significant decrease in 2D angiogenesis tube formation after treatment with these inhibitors. Our data reveal an interesting mechanism of action for Lapatinib and Telatinib in TNBC cells. Collectively, these findings provide preclinical evidence supporting further investigation of HER-2/VEGFR-2 dual targeting as a therapeutic strategy.

References 

  • 1.

    Ferlay, J.; Soerjomataram, I.; Dikshit, R.; et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 2015, 136, E359–386.

  • 2.

    Raza, M.; Kumar, N.; Nair, U.; et al. Current updates on precision therapy for breast cancer associated brain metastasis: Emphasis on combination therapy. Mol. Cell. Biochem. 2021, 476, 3271–3284.

  • 3.

    Bray, F.; Ferlay, J.; Soerjomataram, I.; et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424. https://doi.org/10.3322/caac.21492.

  • 4.

    American Cancer Society. Breast Cancer Facts and Figures 2024–2025; American Cancer Society: Atlanta, GA, USA, 2024; 28p.

  • 5.

    Kuchenbaecker, K.B.; Hopper, J.L.; Barnes, D.R.; et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. Jama 2017, 317, 2402–2416. https://doi.org/10.1001/jama.2017.7112.

  • 6.

    Chen, S.; Parmigiani, G. Meta-analysis of BRCA1 and BRCA2 penetrance. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2007, 25, 1329–1333. https://doi.org/10.1200/jco.2006.09.1066.

  • 7.

    Ford, D.; Easton, D.F.; Bishop, D.T.; et al. Risks of cancer in BRCA1-mutation carriers. Lancet 1994, 343, 692–695.

  • 8.

    Antoniou, A.; Pharoah, P.D.; Narod, S.; et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am. J. Hum. Genet. 2003, 72, 1117–1130.

  • 9.

    Weigelt, B.; Geyer, F.C.; Reis-Filho, J.S. Histological types of breast cancer: How special are they? Mol. Oncol. 2010, 4, 192–208. https://doi.org/10.1016/j.molonc.2010.04.004.

  • 10.

    Diana Schlamadinger, P. Molecular Subtypes of Breast Cancer: Types, Diagnosis, & Treatment Guide. Available online: https://www.bcrf.org/about-breast-cancer/molecular-subtypes-breast-cancer/ (accessed on 1 June 2026).

  • 11.

    McDonald, E.S.; Clark, A.S.; Tchou, J.; et al. Clinical Diagnosis and Management of Breast Cancer. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 2016, 57, 9s–16s. https://doi.org/10.2967/jnumed.115.157834.

  • 12.

    Takada, M.; Toi, M. Cryosurgery for primary breast cancers, its biological impact, and clinical outcomes. Int. J. Clin. Oncol. 2019, 24, 608–613. https://doi.org/10.1007/s10147-019-01448-4.

  • 13.

    Nagini, S. Breast Cancer: Current Molecular Therapeutic Targets and New Players. Anti-Cancer Agents Med. Chem. 2017, 17, 152–163, doi:doi:10.2174/1871520616666160502122724.

  • 14.

    Konig, I.R.; Fuchs, O. What is precision medicine? Eur. Respir. J. 2017, 50, 1700391. https://doi.org/10.1183/13993003.00391-2017.

  • 15.

    Jia, H.; Truica, C.I.; Wang, B.; et al. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects. Drug Resist. Updates 2017, 32, 1–15. https://doi.org/10.1016/j.drup.2017.07.002.

  • 16.

    Bayat Mokhtari, R.; Homayouni, T.S.; Baluch, N.; et al. Combination therapy in combating cancer. Oncotarget 2017, 8, 38022–38043. https://doi.org/10.18632/oncotarget.16723.

  • 17.

    Mishra, V.S.; Kumar, N.; Raza, M.; et al. Amalgamation of PI3K and EZH2 blockade synergistically regulates invasion and angiogenesis: Combination therapy for glioblastoma multiforme. Oncotarget 2020, 11, 4754–4769. https://doi.org/10.18632/oncotarget.27842.

  • 18.

    Braga, S. Resistance to Targeted Therapies in Breast Cancer. In Cancer Drug Resistance; Humana Press: New York, NY, USA, 2016; Volume 1395, pp. 105–136. https://doi.org/10.1007/978-1-4939-3347-1_8.

  • 19.

    Wang, T.; Narayanaswamy, R.; Ren, H.; et al. Combination therapy targeting both cancer stem-like cells and bulk tumor cells for improved efficacy of breast cancer treatment. Cancer Biol. Ther. 2016, 17, 698–707. https://doi.org/10.1080/15384047.2016.1190488.

  • 20.

    Mboge, M.Y.; Mahon, B.P.; McKenna, R.; et al. Carbonic anhydrases: Role in pH control and cancer. Metabolites 2018, 8, 19.

  • 21.

    Shen, Y.; Vignali, P.; Wang, R. Rapid Profiling Cell Cycle by Flow Cytometry Using Concurrent Staining of DNA and Mitotic Markers. Bio-Protocol 2017, 7, e2517. https://doi.org/10.21769/BioProtoc.2517.

  • 22.

    Sivandzade, F.; Bhalerao, A.; Cucullo, L. Analysis of the Mitochondrial Membrane Potential Using the Cationic JC-1 Dye as a Sensitive Fluorescent Probe. Bio-Protocol 2019, 9, e3128. https://doi.org/10.21769/BioProtoc.3128.

  • 23.

    Kumar, N.; Raza, M.; Sehrawat, S. Intuitive repositioning of an anti-depressant drug in combination with tivozanib: Precision medicine for breast cancer therapy. Mol. Cell. Biochem. 2021, 476, 4177–4189.

  • 24.

    Rieger, A.M.; Nelson, K.L.; Konowalchuk, J.D.; et al. Modified annexin V/propidium iodide apoptosis assay for accurate assessment of cell death. J. Vis. Exp. 2011. https://doi.org/10.3791/2597.

  • 25.

    Smith, E.; Palethorpe, H.M.; Tomita, Y.; et al. The Purified Extract from the Medicinal Plant Bacopa monnieri, Bacopaside II, Inhibits Growth of Colon Cancer Cells In Vitro by Inducing Cell Cycle Arrest and Apoptosis. Cells 2018, 7, 81. https://doi.org/10.3390/cells7070081.

  • 26.

    Diaz, B. Invadopodia Detection and Gelatin Degradation Assay. Bio-Protocol 2013, 3, e997. https://doi.org/10.21769/BioProtoc.997.

  • 27.

    Agarwal, S.; Gertler, F.B.; Balsamo, M.; et al. Quantitative assessment of invasive mena isoforms (Menacalc) as an independent prognostic marker in breast cancer. Breast Cancer Res. 2012, 14, R124.

  • 28.

    Wang, Z.; Zhang, H.; Hou, J.; et al. Clinical implications of β-catenin protein expression in breast cancer. Int. J. Clin. Exp. Pathol. 2015, 8, 14989.

  • 29.

    Lin, S.-Y.; Xia, W.; Wang, J.C.; et al. β-catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression. Proc. Natl. Acad. Sci. USA 2000, 97, 4262–4266.

  • 30.

    Mendes, O.; Kim, H.-T.; Stoica, G. Expression of MMP2, MMP9 and MMP3 in breast cancer brain metastasis in a rat model. Clin. Exp. Metastasis 2005, 22, 237–246.

  • 31.

    Yousef, E.M.; Tahir, M.R.; St-Pierre, Y.; et al. MMP-9 expression varies according to molecular subtypes of breast cancer. BMC Cancer 2014, 14, 609.

  • 32.

    La Rocca, G.; Pucci-Minafra, I.; Marrazzo, A.; et al. Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera. Br. J. Cancer 2004, 90, 1414–1421.

  • 33.

    Joseph, C.; Alsaleem, M.; Orah, N.; et al. Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival. Breast Cancer Res. Treat. 2020, 182, 267–282.

  • 34.

    Owyong, M.; Chou, J.; van den Bijgaart, R.J.; et al. MMP9 modulates the metastatic cascade and immune landscape for breast cancer anti-metastatic therapy. Life Sci. Alliance 2019, 2, e201800226.

  • 35.

    Mendes, O.; Kim, H.-T.; Lungu, G.; et al. MMP2 role in breast cancer brain metastasis development and its regulation by TIMP2 and ERK1/2. Clin. Exp. Metastasis 2007, 24, 341–351.

  • 36.

    Nakopoulou, L.; Tsirmpa, I.; Alexandrou, P.; et al. MMP-2 protein in invasive breast cancer and the impact of MMP-2/TIMP-2 phenotype on overall survival. Breast Cancer Res. Treat. 2003, 77, 145–155.

  • 37.

    Baranwal, S.; Alahari, S.K. Molecular mechanisms controlling E-cadherin expression in breast cancer. Biochem. Biophys. Res. Commun. 2009, 384, 6–11.

  • 38.

    Singhai, R.; Patil, V.W.; Jaiswal, S.R.; et al. E-Cadherin as a diagnostic biomarker in breast cancer. N. Am. J. Med. Sci. 2011, 3, 227.

  • 39.

    Kleer, C.G.; van Golen, K.L.; Braun, T.; et al. Persistent E-cadherin expression in inflammatory breast cancer. Mod. Pathol. 2001, 14, 458–464.

  • 40.

    Jiang, P.; Enomoto, A.; Takahashi, M. Cell biology of the movement of breast cancer cells: Intracellular signalling and the actin cytoskeleton. Cancer Lett. 2009, 284, 122–130.

  • 41.

    Pollard, T.D.; Borisy, G.G. Cellular motility driven by assembly and disassembly of actin filaments. Cell 2003, 112, 453–465.

  • 42.

    Roussos, E.T.; Goswami, S.; Balsamo, M.; et al. Mena invasive (Mena INV) and Mena11a isoforms play distinct roles in breast cancer cell cohesion and association with TMEM. Clin. Exp. Metastasis 2011, 28, 515–527.

  • 43.

    Oudin, M.J.; Barbier, L.; Schäfer, C.; et al. MENA confers resistance to paclitaxel in triple-negative breast cancer. Mol. Cancer Ther. 2017, 16, 143–155.

  • 44.

    Martin, T.A.; Mansel, R.E.; Jiang, W.G. Loss of occludin leads to the progression of human breast cancer. Int. J. Mol. Med. 2010, 26, 723–734. https://doi.org/10.3892/ijmm_00000519.

  • 45.

    Moses, H.; Barcellos-Hoff, M.H. TGF-β biology in mammary development and breast cancer. Cold Spring Harb. Perspect. Biol. 2011, 3, a003277.

  • 46.

    Qiu, L.-X.; Yao, L.; Mao, C.; et al. TGFB1 L10P polymorphism is associated with breast cancer susceptibility: Evidence from a meta-analysis involving 47,817 subjects. Breast Cancer Res. Treat. 2010, 123, 563–567.

  • 47.

    Scollen, S.; Luccarini, C.; Baynes, C.; et al. TGF-β signaling pathway and breast cancer susceptibility. Cancer Epidemiol. Prev. Biomark. 2011, 20, 1112–1119.

  • 48.

    Bergom, C.; Gao, C.; Newman, P.J. Mechanisms of PECAM-1-mediated cytoprotection and implications for cancer cell survival. Leuk. Lymphoma 2005, 46, 1409–1421.

  • 49.

    Cao, G.; O’Brien, C.D.; Zhou, Z.; et al. Involvement of human PECAM-1 in angiogenesis and in vitro endothelial cell migration. Am. J. Physiol.-Cell Physiol. 2002, 282, C1181–C1190.

  • 50.

    Rydén, L.; Linderholm, B.; Nielsen, N.H.; et al. Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer. Breast Cancer Res. Treat. 2003, 82, 147–154.

  • 51.

    Yan, J.-D.; Liu, Y.; Zhang, Z.-Y.; et al. Expression and prognostic significance of VEGFR-2 in breast cancer. Pathol.-Res. Pract. 2015, 211, 539–543.

  • 52.

    Zhao, J.; Yang, C.; Guo, S.; et al. GM130 regulates epithelial-to-mesenchymal transition and invasion of gastric cancer cells via snail. Int. J. Clin. Exp. Pathol. 2015, 8, 10784.

  • 53.

    Foley, J.; Nickerson, N.K.; Nam, S.; et al. EGFR signaling in breast cancer: Bad to the bone. Semin. Cell Dev.Biol. 2010, 21, 951–960.

  • 54.

    Maennling, A.E.; Tur, M.K.; Niebert, M.; et al. Molecular targeting therapy against EGFR family in breast cancer: Progress and future potentials. Cancers 2019, 11, 1826.

  • 55.

    Ali, R.; Wendt, M.K. The paradoxical functions of EGFR during breast cancer progression. Signal Transduct. Target. Ther. 2017, 2, 16042.

  • 56.

    Ham, S.A.; Yoo, T.; Lee, W.J.; et al. ADAMTS1-mediated targeting of TSP-1 by PPARδ suppresses migration and invasion of breast cancer cells. Oncotarget 2017, 8, 94091.

  • 57.

    Tyan, S.-W.; Hsu, C.-H.; Peng, K.-L.; et al. Breast cancer cells induce stromal fibroblasts to secrete ADAMTS1 for cancer invasion through an epigenetic change. PLoS ONE 2012, 7, e35128.

  • 58.

    Tan, I.A.; Frewin, K.; Ricciardelli, C.; et al. ADAMTS1 promotes adhesion to extracellular matrix proteins and predicts prognosis in early stage breast cancer patients. Cell Physiol Biochem. 2019, 52, 1553–1568.

  • 59.

    Yang, C.; He, P.; Liu, Y.; et al. Down-regulation of CEACAM1 in breast cancer. Acta Biochim. Biophys. Sin. 2015, 47, 788–794.

  • 60.

    Wang, J.-L.; Sun, S.-Z.; Qu, X.; et al. Clinicopathological significance of CEACAM1 gene expression in breast cancer. Chin. J. Physiol. 2011, 54, 332–338.

  • 61.

    Yang, C.; He, P.; Liu, Y.; et al. Assay of serum CEACAM1 as a potential biomarker for breast cancer. Clin. Chim. Acta 2015, 450, 277–281.

  • 62.

    Bamberger, A.-M.; Kappes, H.; Methner, C.; et al. Expression of the adhesion molecule CEACAM1 (CD66a, BGP, C-CAM) in breast cancer is associated with the expression of the tumor-suppressor genes Rb, Rb2, and p27. Virchows Arch. 2002, 440, 139–144.

  • 63.

    Sorlie, T.; Perou, C.M.; Tibshirani, R.; et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 2001, 98, 10869–10874. https://doi.org/10.1073/pnas.191367098.

  • 64.

    Raza, M.; Prasad, P.; Gupta, P.; et al. Perspectives on the role of brain cellular players in cancer-associated brain metastasis: Translational approach to understand molecular mechanism of tumor progression. Cancer Metastasis Rev. 2018, 37, 791–804. https://doi.org/10.1007/s10555-018-9766-5.

  • 65.

    Zhou, W.; Slingerland, J.M. Links between oestrogen receptor activation and proteolysis: Relevance to hormone-regulated cancer therapy. Nat. Rev. Cancer 2014, 14, 26–38.

  • 66.

    Group, E.B.C.T.C. Tamoxifen for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 1998, 351, 1451–1467. https://doi.org/10.1016/S0140-6736(97)11423-4.

  • 67.

    Romond, E.H.; Perez, E.A.; Bryant, J.; et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 2005, 353, 1673–1684. https://doi.org/10.1056/NEJMoa052122.

  • 68.

    Stringer-Reasor, E.M.; May, J.E.; Olariu, E.; et al. An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer. Breast Cancer Res. 2021, 23, 30. https://doi.org/10.1186/s13058-021-01408-9.

  • 69.

    Luque-Cabal, M.; Garcia-Teijido, P.; Fernandez-Perez, Y.; et al. Mechanisms Behind the Resistance to Trastuzumab in HER2-Amplified Breast Cancer and Strategies to Overcome It. Clin. Med. Insights. Oncol. 2016, 10, 21–30. https://doi.org/10.4137/cmo.s34537.

  • 70.

    Palethorpe, H.M.; Smith, E. Bacopasides I and II Act in Synergy to Inhibit the Growth, Migration and Invasion of Breast Cancer Cell Lines. Molecules 2019, 24, 3539. https://doi.org/10.3390/molecules24193539.

  • 71.

    Lehmann, B.D.; Bauer, J.A.; Chen, X.; et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Investig. 2011, 121, 2750–2767. https://doi.org/10.1172/jci45014.

  • 72.

    Yersal, O.; Barutca, S. Biological subtypes of breast cancer: Prognostic and therapeutic implications. World J. Clin. Oncol. 2014, 5, 412–424. https://doi.org/10.5306/wjco.v5.i3.412.

  • 73.

    Lebert, J.M.; Lester, R.; Powell, E.; et al. Advances in the systemic treatment of triple-negative breast cancer. Curr. Oncol. 2018, 25, S142–S150. https://doi.org/10.3747/co.25.3954.

  • 74.

    DeMichele, A.; Yee, D.; Esserman, L. Mechanisms of Resistance to Neoadjuvant Chemotherapy in Breast Cancer. N. Engl. J. Med. 2017, 377, 2287–2289. https://doi.org/10.1056/NEJMcibr1711545.

  • 75.

    Lin, N.U.; Claus, E.; Sohl, J.; et al. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: High incidence of central nervous system metastases. Cancer 2008, 113, 2638–2645. https://doi.org/10.1002/cncr.23930.

  • 76.

    Kassam, F.; Enright, K.; Dent, R.; et al. Survival outcomes for patients with metastatic triple-negative breast cancer: Implications for clinical practice and trial design. Clin. Breast Cancer 2009, 9, 29–33. https://doi.org/10.3816/CBC.2009.n.005.

  • 77.

    Agulnik, M.; Cohen, E.W.; Cohen, R.B.; et al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2007, 25, 3978–3984. https://doi.org/10.1200/jco.2007.11.8612.

  • 78.

    Harrington, K.J.; El-Hariry, I.A.; Holford, C.S.; et al. Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2009, 27, 1100–1107. https://doi.org/10.1200/jco.2008.17.5349.

  • 79.

    Polychronis, A.; Sinnett, H.D.; Hadjiminas, D.; et al. Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: A double-blind placebo-controlled phase II randomised trial. Lancet. Oncol. 2005, 6, 383–391. https://doi.org/10.1016/s1470-2045(05)70176-5.

  • 80.

    Arteaga, C.L.; O’Neill, A.; Moulder, S.L.; et al. A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2008, 14, 6277–6283. https://doi.org/10.1158/1078-0432.ccr-08-0482.

  • 81.

    Rexer, B.N.; Engelman, J.A.; Arteaga, C.L. Overcoming resistance to tyrosine kinase inhibitors: Lessons learned from cancer cells treated with EGFR antagonists. Cell Cycle 2009, 8, 18–22. https://doi.org/10.4161/cc.8.1.7324.

  • 82.

    Cristofanilli, M.; Valero, V.; Mangalik, A.; et al. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2010, 16, 1904–1914. https://doi.org/10.1158/1078-0432.ccr-09-2282.

  • 83.

    Liu, C.Y.; Hu, M.H.; Hsu, C.J.; et al. Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells. Oncotarget 2016, 7, 9135–9149. https://doi.org/10.18632/oncotarget.7035.

  • 84.

    Liu, Z.; Fusi, A.; Schmittel, A.; et al. Eradication of EGFR-positive circulating tumor cells and objective tumor response with lapatinib and capecitabine. Cancer Biol. Ther. 2010, 10, 860–864. https://doi.org/10.4161/cbt.10.9.13323.

  • 85.

    Takahashi, K.; Tanaka, M.; Inagaki, A.; et al. Establishment of a 5-fluorouracil-resistant triple-negative breast cancer cell line. Int. J. Oncol. 2013, 43, 1985–1991. https://doi.org/10.3892/ijo.2013.2135.

  • 86.

    Witzel, I.; Oliveira-Ferrer, L.; Pantel, K.; et al. Breast cancer brain metastases: Biology and new clinical perspectives. Breast Cancer Res. 2016, 18, 8. https://doi.org/10.1186/s13058-015-0665-1.

  • 87.

    Ma, S.; Dielschneider, R.F.; Henson, E.S.; et al. Ferroptosis and autophagy induced cell death occur independently after siramesine and lapatinib treatment in breast cancer cells. PloS ONE 2017, 12, e0182921. https://doi.org/10.1371/journal.pone.0182921.

  • 88.

    Guan, M.; Tong, Y.; Guan, M.; et al. Lapatinib Inhibits Breast Cancer Cell Proliferation by Influencing PKM2 Expression. Technol. Cancer Res. Treat. 2018, 17, 1533034617749418. https://doi.org/10.1177/1533034617749418.

Share this article:
Download PDF
DOI
10.53941/jiim.2026.100005
Issue
Volume 2, Issue 2
How to Cite
Raza, M.; Kumar, N.; Sehrawat, S. Dual Targeting of HER-2 and VEGFR-2 Receptors in Breast Cancer-Associated Migration and Metastasis. Journal of Inflammatory and Infectious Medicine 2026, 2 (2), 2. https://doi.org/10.53941/jiim.2026.100005.
RIS
BibTex
Copyright & License
article copyright Image
Copyright (c) 2026 by the authors.